On April 15, 2025, President Donald J. Trump announced an Executive Order aimed at lowering prescription drug prices, building on efforts from his first term. The Order directs the Department of Health and Human Services to implement measures that will enhance the Medicare Drug Pricing Negotiation Program, align Medicare payments with actual drug acquisition costs, and standardize drug pricing across various care settings. It also seeks to provide substantial discounts on essential medications for low-income patients, particularly insulin and epinephrine, and encourages states to explore drug importation programs for additional cost savings.

The Executive Order emphasizes the creation of a transparent and competitive prescription drug market by increasing the availability of generics and biosimilars, which are generally less expensive than brand-name drugs. It includes measures to improve the disclosure of fees processed by pharmaceutical benefit managers and aims to reform the prescription drug value chain to enhance competition and accountability. These actions reflect President Trump’s commitment to prioritize American patients, contrasting with the previous administration’s approach to drug pricing initiatives.

Overall, this announcement underscores the administration’s focus on reducing healthcare costs for Americans while promoting transparency and competition within the pharmaceutical industry. The proposed changes are expected to strengthen Medicare’s pricing power and provide meaningful financial relief to low-income individuals who rely on essential medications. The administration’s efforts are part of a broader strategy to tackle the challenges of high prescription drug prices in the United States.

Original: article